Home / Business and Economy / Spectral AI's Burn System Gains FDA Clearance
Spectral AI's Burn System Gains FDA Clearance
12 Aug
Summary
- DeepView System received FDA De Novo clearance in May for burn assessment.
- The company reiterated $18.5 million revenue guidance for 2026.
- Commercial model includes system sales, software, and service revenue.
Spectral AI's second-quarter results signaled a pivot to commercialization, highlighted by the U.S. Food and Drug Administration's De Novo clearance of its DeepView System in May for burn assessment. The company maintained its 2026 revenue forecast of about $18.5 million, which does not factor in significant DeepView sales.
CEO Vincent Capone stated the FDA clearance paves the way for a deliberate U.S. and international rollout. The focus will be on clinician awareness, infrastructure development, and pursuing additional diagnostic indications for the AI-driven imaging system. Commercialization plans involve system capital purchases or leases, followed by recurring software and service revenue over minimum three-year terms.
Spectral AI aims to deploy up to 30 DeepView systems in U.S. burn and trauma centers through June 30, 2027, supported by BARDA funding under a Project BioShield contract. The company is expanding its commercial team, currently consisting of two personnel, with plans for at least two additional hires.
